The data presented support use of MR vaccine at 6 months to protect young infants during measles outbreaks and in settings ...

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

TIVDAK is approved for the treatment of recurrent or metastatic cervical cancer in the European Union, United States and Japan ...

A study conducted by Prof. Thai-Yen Ling at National Taiwan University underscores the potential of small extracellular ...

Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy ...

AstraZeneca’s Imfinzi receives US FDA approval for patients with muscle-invasive bladder cancer: Cambridge, UK Tuesday, April 1, 2025, 10:00 Hrs [IST] AstraZeneca’s Imfinzi (d ...

Equities research analysts at StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZ – Get Free Report) in a note issued to investors on Monday. The brokerage set a “hold” rating on the ...

FMC Corporation , a leading global agricultural sciences company, today announced an agreement with Bayer to commercialize products containing Isoflextm active in the European Union (EU) and Great ...

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer (MIBC).

Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET. Company Participants. Douglas Onsi - President ...